Dr. Christel Claes received her PhD in 2018 from the Catholic University of Leuven, Belgium, where she studied the effect of TREM2 mutations on human stem cell (hPSC)-derived microglia in vitro under the supervision of Dr. Catherine Verfaillie, an expert in human stem cell modeling and Dr. Bart De Strooper, a renowned scientist in the field of Alzheimer’s disease. During her PhD Dr. Claes was awarded with an EMBO short-term fellowship to perform research abroad, at the DZNE in Munich, Germany, where she optimized the co-culture of hPSC-derived microglia on ex vivo brain slices containing amyloid plaques. She then began her post-doctoral training in the lab of Dr. Mathew Blurton-Jones at the University of California, Irvine (2018-current), one of the pioneers of human stem cell-derived microglia research, in order to study the effect of TREM2 mutations on human microglial biology and Alzheimer pathology in chimeric Alzheimer mice.
Christel Claes, PhD
First published on: November 24, 2020
Last modified on: November 22, 2024